The efficacy of rubicatin in the treatment of lung cancer

Lurbinectedin (Lurbinectedin) is an innovative drug for the treatment of lung cancer, and its efficacy has been verified through multiple clinical trials. The drug has shown significant efficacy in the treatment of small cell lung cancer (SCLC), particularly in patients with metastatic SCLC whose disease has progressed after platinum-based chemotherapy.

Approval of rubicatin for SCLC is accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent on verification and description of clinical benefit in confirmatory trials.

USFDA approval Rubicatin Treatment SCLC is based on a Phase 2 open-label, single-arm study that enrolled 105 patients with SCLC at 26 hospitals in 6 countries in Europe and the United States. Patients were treated with Rubicatin 3.2 mg/m2 as a 60-minute intravenous infusion repeated every 21 days until disease progression or unacceptable toxicity. The primary endpoint was overall response rate (ORR) of 35%, and the median duration of response was 5.3 months as measured by investigator assessment (30% and 5.1 months as measured by IRC).

Although Rubicatin is not currently on sale in China, patients in urgent need can purchase it overseas or contact professional overseas medical consulting companies. The only one currently available on the market is the original version of Rubicatin, produced by Spain's PharmanMar biopharmaceutical company. The price of this 4 mg drug is NT$34,000 per box in Singapore and NT$91,000 per box in the United States.

In summary, rubicatin has demonstrated significant efficacy in the treatment of small cell lung cancer, demonstrating its unique advantages as an innovative drug in terms of overall effectiveness, disease control rate, duration of response and progression-free survival.